AEON Biopharma (AEON) vs BioVie (BIVI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
BioVie (BIVI) has outperformed AEON Biopharma (AEON) over the past year, losing 38.2% versus a loss of 85.2%. AEON Biopharma is the larger company by market cap ($10.3 million vs $8.6 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AEON | BIVI |
|---|---|---|
| Share price | $0.123 | $0.80 |
| Market cap | $10.35M | $8.58M |
| 1-day change | -7.59% | -12.07% |
| YTD return | -88.82% | -31.03% |
| 1-year return | -85.18% | -38.22% |
| 5-year return | — | -99.87% |
| EPS (TTM) | $-3.89 | $-2.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-39.22M | $-22.07M |
| 52-week high | $1.45 | $3.79 |
| 52-week low | $0.106 | $0.7515 |
| Distance from 52-week high | -91.52% | -78.89% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +1379.67% | +557.50% |
| Average volume | 7.44M | 568.61K |
| Shares outstanding | 84.12M | 10.72M |
| Employees | 8 | 13 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BIVI has outperformed AEON by 47.0 percentage points over the past year.
About AEON Biopharma
AEON stock →AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
About BioVie
BIVI stock →BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
AEON vs BIVI FAQ
Which is bigger, AEON Biopharma or BioVie?
AEON Biopharma (AEON) is larger, with a market capitalization of $10.35M compared with $8.58M for BioVie (BIVI).
Which stock has performed better over the past year, AEON or BIVI?
BIVI returned -38.22% over the past 12 months, compared with -85.18% for AEON (price return, excluding dividends). Past performance does not predict future results.
Are AEON Biopharma and BioVie in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.